Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia - Contacts and Locations

Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia

This study is currently recruiting participants.

Study NCT00565175. Last updated on January 3, 2008. Information provided by Helsinki University

Please refer to this study by its ClinicalTrials.gov identifier: NCT00565175

Contacts


Contact: Jesper Ekelund, MD-PhD	+358-50-3317987	Jesper.Ekelund@ktl.fi

Locations


Finland
	Lohjan sairaanhoitoalue	Not yet recruiting
	Lohja, Finland, 08450
	Contact: Jarmo Laitinen, MD +358-19-3801 700 Jarmo.Laitinen@hus.fi
	Sub-Investigator: Hannu Saloheimo, MD
	Principal Investigator: Jarmo Laitinen, MD
	Kellokosken sairaala	Recruiting
	Kellokoski, Finland, 04500
	Contact: Grigori Joffe, MD-PhD +358-9-2716 3220 Grigori.Joffe@hus.fi
	Principal Investigator: Grigori Joffe, MD-PhD
	Peijaksen sairaala	Not yet recruiting
	Vantaa, Finland, 01450
	Contact: Yrjo Lahteenlahti, MD +358-9-471 66530 Yrjo.Lahteenlahti@hus.fi
	Principal Investigator: Yrjo Lahteenlahti, MD
	HUCH Department of Psychiatry	Recruiting
	Helsinki, Finland, 10029
	Contact: Jesper Ekelund, MD-PhD +358-9-4711 Jesper.Ekelund@hus.fi
	Principal Investigator: Jesper Ekelund, MD-PhD

Sponsors and Collaborators

Helsinki University

Finland: Lilly saatio foundation

Investigators


Principal Investigator:	Jesper Ekelund, MD-PhD	Helsinki University